Abivax unveils key data on obefazimod at Digestive Disease Week

Abivax, a biotechnology company specializing in chronic inflammatory diseases, will present nine scientific abstracts on obefazimod at Digestive Disease Week 2026 in Chicago. The data, from the Phase 3 ABTECT program, focus on the efficacy and tolerability of the treatment for ulcerative colitis. The results include patient-reported improvements in quality of life and fatigue, as well as preclinical evidence of antifibrotic activity. Abivax executives emphasize that these results strengthen confidence in obefazimod as a potential therapeutic advance.